Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Apel­lis Phar­ma­ceu­ti­cals still can’t pin­point ex­act­ly what’s be­hind the rare cas­es of eye in­flam­ma­tion that’s been re­port­ed in pa­tients tak­ing its ge­o­graph­ic at­ro­phy drug Syfovre …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER